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Abstract 
Background: This post hoc analysis examined the efficacy and safety of twice-daily insulin lispro low mixture (LM25) 
and once-daily basal insulin glargine plus once-daily prandial insulin lispro (IGL) in a Latin American subpopulation 
with type 2 diabetes mellitus (T2DM).
Methods: A phase 4, randomized, open-label, parallel-arm trial included participants aged 18–75 years with T2DM tak-
ing once-daily insulin glargine and stable doses of metformin and/or pioglitazone with glycated hemoglobin (HbA1c) 
7.5–10.5 % and fasting plasma glucose ≤121 mg/dL. Participants were randomized 1:1 to receive their stable dose of 
metformin and/or pioglitazone plus twice-daily LM25 or IGL for 24 weeks. The primary efficacy outcome was change in 
HbA1c after 24 weeks of treatment. Results from participants in Argentina, Brazil, and Mexico are presented here.
Results: 162 participants (80 LM25; 82 IGL) with mean ± standard deviation (SD) age = 57.3 ± 9.0 years and 
body mass index = 31.3 ± 5.2 kg/m2 were included. Mean ± SD change in HbA1c from baseline to week 24 was 
−1.5 ± 1.0 % (LM25) and −1.1 ± 1.2 % (IGL). At week 24, 35.1 % (LM25) and 31.6 % (IGL) of participants achieved 
HbA1c <7.0 %. Mean ± SD weight gain from baseline to week 24 was 2.4 ± 2.9 kg in the LM25 group and 1.0 ± 3.1 kg 
in the IGL group. The mean ± SD rates of total hypoglycemia per year were 18.9 ± 27.3 (LM25) and 21.6 ± 31.1 (IGL). 
Rates of treatment-emergent adverse events were 46 % (LM25) and 39 % (IGL).
Conclusions: Our results suggest that both LM25 and IGL are viable treatment options for insulin intensification 
in Latin American patients with T2DM with suboptimal glycemic control on basal insulin glargine. The safety and 
tolerability profiles of LM25 and IGL are consistent between this Latin American population and the global trial-level 
population.
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Background
Type 2 diabetes mellitus (T2DM) is an important health 
problem in Latin America, particularly in Brazil and Mexico, 
which respectively have the fourth and sixth largest popula-
tions of people with diabetes in the world [1]. In 2014, the 
prevalence of T2DM in South and Central America was 
8.1 % (24.8 million patients) [2] and is projected to increase 
by 60 % (to 38.5 million patients) by 2035 [1]. This increase 
is partly caused by changes in diet and lifestyle, e.g., urbani-
zation, an increase in the consumption of animal products 
and processed foods, and increases in patient body mass 
[3–5]. Moreover, only 36 % of patients with T2DM in Latin 
America and only 26 % in Brazil have a glycated hemoglobin 
level (HbA1c) at the recommended level of  <7.0  % [6, 7]. 
Considering the changing lifestyle and the increasing preva-
lence of T2DM in the region, current scientific evidence on 
insulin intensification strategies from global populations 
must be verified in a Latin American population.
As T2DM progresses, there is a decline in insulin secre-
tory capacity such that, for most patients, treatment with 
insulin must be initiated to achieve the target HbA1c ≤7 % 
[8]. The Latin American Diabetes Association (ALAD) 
guidelines recommend initiating insulin therapy with a 
long-acting basal insulin analogue, such as insulin glar-
gine, in combination with oral agents for patients who fail 
to achieve target HbA1c on oral agents alone [3]. Unfortu-
nately, the long-term efficacy of basal insulin therapy alone 
is often limited [9], with less than 50 % of patients reaching 
target HbA1c, commonly due to excessive postprandial gly-
cemic excursions [10]. Therefore, most patients with T2DM 
will require an intensification of their insulin therapy.
The ALAD guidelines recommend intensifying insulin 
therapy with a combination of 2 types of insulin [3]. To this 
end, there are 2 possible strategies for intensifying insulin 
therapy: switching to a premixed combination of long-acting 
and short-acting insulin administered twice daily [3, 10] or 
continuing on basal insulin and adding rapid-acting insulin 
before meals [3, 11]. There are few data directly comparing 
these 2 insulin intensification strategies in Latin American 
patients with T2DM inadequately controlled by basal insu-
lin plus oral antidiabetic agents. This post hoc analysis of a 
multinational clinical trial compared the efficacy and safety 
of twice-daily insulin lispro low mixture (LM25) and once-
daily basal insulin glargine plus once-daily prandial insulin 
lispro (IGL) in Latin American patients with T2DM who 
had not achieved target HbA1c on once-daily basal insulin 
glargine with metformin and/or pioglitazone.
Methods
Study design
This study was a post hoc analysis of a subpopulation of 
Latin American participants from a multinational, rand-
omized, open-label, noninferiority, phase 4 clinical trial 
designed to examine the efficacy and safety of 2 insu-
lin intensification strategies in patients with T2DM not 
adequately controlled on once-daily basal insulin glar-
gine with metformin and/or pioglitazone [12]. The global 
study was approved by an independent ethical review 
board at each study site and was conducted in accord-
ance with the Declaration of Helsinki, the International 
Conference on Harmonisation Good Clinical Practice 
standards, and all local laws and regulations in the study 
countries. The trial was registered with ClinicalTrials.
gov: NCT01175824. All participants provided written 
informed consent.
Study population
In the global study, participants were enrolled at 55 study 
sites in Argentina, Brazil, China, Egypt, India, Republic 
of Korea, México, Romania, Russian Federation, Spain, 
and Turkey. This post hoc analysis included data from 
participants who were enrolled in Latin America (Argen-
tina, Brazil, and Mexico).
The inclusion criteria were: age 18–75  years; a diag-
nosis of T2DM consistent with the World Health 
Organization Classification of Diabetes [13]; HbA1c 
7.5–10.5  %; current regimen of stable doses of met-
formin (≥1500  mg/day for at least 8  weeks) and/or 
pioglitazone (≥30  mg/day for at least 12  weeks); a cur-
rent stable regimen of once-daily basal insulin glargine 
for at least 90 days before screening; and fasting plasma 
glucose ≤121 mg/dL, determined by the central labora-
tory, or  >121  mg/dL if the investigator determined fur-
ther titration of basal insulin glargine was not possible for 
safety reasons. Exclusion criteria were: a screening body 
mass index >45 kg/m2; more than 1 severe hypoglycemic 
episode within 24 weeks before screening; and a history 
of using drugs contraindicated for use with the study 
drugs.
At the screening visit, demographic and clinical data 
were collected from all participants. Participants also 
underwent a physical examination and provided a fasting 
plasma glucose (FPG) sample for measurement in a cen-
tral laboratory.
Treatment protocol
The trial treatment protocol has been described in detail 
previously [12]. Briefly, participants were randomized 
to receive subcutaneous twice-daily LM25 (insulin lis-
pro low mixture; 75  % insulin lispro protamine suspen-
sion and 25 % insulin lispro solution) or IGL (once-daily 
basal insulin glargine and once-daily prandial insulin lis-
pro), in addition to their stable dose of metformin and/
or pioglitazone, for 24  weeks. LM25 was administered 
before breakfast and dinner. Insulin glargine was admin-
istered at bedtime. Insulin lispro was administered before 
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the largest meal of the day. The largest meal of the day 
was defined as the meal with the highest 2-h postprandial 
blood glucose concentration and was determined during 
the screening period. LM25, insulin glargine, and insulin 
lispro were administered using 100 U/mL prefilled pens.
Outcome measures
The primary efficacy endpoint was the change in HbA1c 
from baseline to week 24. The secondary efficacy end-
points were the percentage of participants reaching the 
HbA1c target levels <7.0 and ≤6.5 %, the change in FPG 
concentration from baseline to week 24, 7-point self-
monitoring of blood glucose (SMBG) profiles at baseline 
and week 24, glycemic variability at week 24 [as meas-
ured by the standard deviation (SD)] in 7-point SMBG 
profiles, daily total, basal, and prandial insulin doses at 
week 24, and change in body weight at week 24.
Safety endpoints included treatment-emergent adverse 
events (TEAEs), and the incidence, rate, and severity of 
hypoglycemic episodes. In addition, participant satisfac-
tion with insulin treatment was measured using the insulin 
treatment satisfaction questionnaire (ITSQ) [14]. Partici-
pant perceptions about the acceptability and effectiveness 
of diabetes medications and perceived adverse effects were 
measured using the perceptions about medications-diabe-
tes 21 (PAM-D21) questionnaire [15]. Total scores on the 
ITSQ range from 0 to 100, where 100 indicates complete 
satisfaction with insulin treatment. Subscale scores on the 
PAM-D21 range from 0 to 100, where higher scores indi-
cate better perceptions about diabetes medications.
Statistical analysis
The intent-to-treat (ITT) and safety populations were 
both defined as all randomized participants who received 
at least 1 dose of study drug. Efficacy and health outcome 
endpoints were analyzed using the ITT population. Sum-
mary statistics were calculated by treatment group for 
all endpoints. Due to the relatively small sample size, no 




A total of 248 patients were screened for study entry in 
Latin America. Of these, 162 were eligible for inclusion 
in the study and received at least 1 dose of study drug, 12 
discontinued, and 150 completed the study (Fig. 1).
Baseline characteristics
Baseline demographic and clinical characteristics are 
summarized in Table 1.
Efficacy
With respect to the primary outcome, the mean  ±  SD 
change in HbA1c from baseline to week 24 was 
−1.5 ± 1.0 % in the LM25 group and −1.1 ± 1.2 % in the 
IGL group. The mean ± SD change in HbA1c from base-
line to week 12 was −1.4 ± 1.0 % in the LM25 group and 
−1.1 ± 1.1 % in the IGL group. The observed HbA1c lev-
els throughout the study are presented in Fig. 2.
A total of 35.1  % (26/74) of participants in the LM25 
group and 31.6 % (24/76) of participants in the IGL group 
achieved HbA1c ≤7.0 %. A total of 14.9 % (11/74) of par-
ticipants in the LM25 group and 15.8  % (12/76) of par-
ticipants in the IGL group achieved HbA1c ≤6.5 %.
The mean ± SD FPG at week 24 was 125.5 ± 42.9 mg/
dL in the LM25 group and 121.0 ± 39.9 mg/dL in the IGL 
group. The mean ± SD change in FPG from baseline to 
week 24 was 17.6 ± 55.2 mg/dL in the LM25 group and 
21.6 ± 46.9 mg/dL in the IGL group. The mean ± SD gly-
cemic variability at baseline was 46.6 ± 18.8 in the LM25 
group and 49.7 ± 18.6 in the IGL group. The mean ± SD 
changes in glycemic variability from baseline to week 24 
were −9.0 ± 17.3 mg/dL (LM25) and −10.4 ± 17.9 mg/
dL (IGL).
The mean unadjusted 7-point SMBG levels at baseline 
and week 24 are presented in Fig. 3.
Total daily, basal, and prandial insulin doses at base-
line and week 24 are presented in Table 2. Of the patients 
in the IGL group, 10 received prandial insulin lispro at 
breakfast, 40 at lunch, and 32 at dinner.
Participants in both treatment groups experienced 
weight gain. The mean  ±  SD changes in body weight 
from baseline to week 24 were 2.4 ± 2.9 kg (LM25) and 
1.0 ± 3.1 kg (IGL).
Safety and tolerability
At least 1 TEAE was reported by 46  % (37/80) of par-
ticipants in the LM25 group and 39  % (32/82) of par-
ticipants in the IGL group. Of these, 7.5  % (6/80) of 
participants in the LM25 group and 4.9 % (4/82) of par-
ticipants in the IGL group reported TEAEs that were 
considered to possibly be related to the study drugs. 
Serious TEAEs were reported by 3.8 % (3/80) of partici-
pants in the LM25 group and 3.7 % (3/82) of participants 
in the IGL group. One participant in each group discon-
tinued due to adverse events and no participants died 
during the study.
Overall, approximately 70  % (113/162) of participants 
experienced at least 1 episode of hypoglycemia during 
the study (Table  3). Severe hypoglycemia was experi-
enced by 1.3 % (1/80) of participants in the LM25 group 
and no participants in the IGL group.
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Participants screened (N=248) 
Participants randomized (N=162) 
Entry criteria not met (n=83) 
Lost to follow up (n=2) 
Participant withdrawal (n=1) 
IGL (n=82) LM25 (n=80) 
Received least one dose of study drug (n=82) 
 
Completed study (n=76) 
Discontinued study (n=6) 
Adverse event (n=1) 
Entry criteria not met (n=1) 
Physician decision (n=1) 
Participant withdrawal (n=3) 
Received least one dose of study drug (n=80) 
 
Completed study (n=74) 
Discontinued study (n=6) 
Adverse event (n=1) 
Entry criteria not met (n=3) 
Lack of efficacy (n=2) 
Fig. 1 Participant disposition. Summary of participant disposition of Latin American participants with type 2 diabetes mellitus who were treated 
with LM25 or IGL for 24 weeks. IGL once-daily basal insulin glargine plus once-daily prandial insulin lispro, LM25 75 % insulin lispro protamine sus-
pension and 25 % insulin lispro solution
Table 1 Demographic and baseline characteristics
BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin, IGL once-daily basal insulin glargine plus once-daily prandial insulin lispro, 
IU international units, LM25 75 % insulin lispro protamine suspension and 25 % insulin lispro solution, SD standard deviation
Characteristic LM25 (N = 80) IGL (N = 82) Total (N = 162)
Country, n (%)
 Argentina 40 (50.0) 39 (47.6) 79 (48.8)
 Brazil 20 (25.0) 23 (28.0) 43 (26.5)
 Mexico 20 (25.0) 20 (24.4) 40 (24.7)
Sex, n (%)
 Male 39 (48.8) 30 (36.6) 69 (42.6)
 Female 41 (51.3) 52 (63.4) 93 (57.4)
Age (years), mean (SD) 57.5 (9.7) 57.1 (8.4) 57.3 (9.0)
Weight (kg), mean (SD) 82.5 (15.4 81.8 (15.0) 82.2 (15.1)
BMI (kg/m2), mean (SD) 30.9 (4.8) 31.7 (5.5) 31.3 (5.2)
Duration of diabetes (years), mean (SD) 13.8 (7.9) 12.9 (6.8) 13.4 (7.3)
HbA1c at screening
 %, mean (SD) 8.8 (0.8) 8.6 (0.8) 8.7 (0.8)
 <8.5 %, n (%) 33 (41.3) 35 (42.7) 68 (42.0)
FPG (mg/dL), mean (SD) 107.1 (37.1) 98.5 (28.2) 102.8 (33.0)
Insulin glargine dose at screening (IU),  mean (SD) 39.3 (19.3) 39.5 (18.9) 39.4 (19.0)
Glycemic variability (mg/dL), mean (SD) 46.6 (18.8) 49.7 (18.6) 48.2 (18.7)
Concomitant oral antidiabetic drugs
 Metformin, n (%) 80 (100) 82 (100) 162 (100)
  Daily dose (mg), mean (SD) 1968.1 (393.0) 2062.8 (396.8) 2016.0 (396.6)
 Pioglitazone, n (%) 4 (5.0) 5 (6.1) 9 (5.6)
  Daily dose (mg), mean (SD) 30.0 (0.0) 30.0 (0.0) 30.0 (0.0)
 Metformin and pioglitazone, n (%) 4 (5.0) 5 (6.1) 9 (5.6)
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Health outcomes
The mean changes in ITSQ and PAM-D21 from baseline 
to week 24 are presented in Table 4.
Discussion
To our knowledge, this is the first report to disclose 
results from a Latin American subpopulation in a study 
comparing a twice-daily premixed insulin regimen with 
a once-daily basal insulin plus once-daily prandial insu-
lin regimen in patients with T2DM not adequately 
controlled on insulin glargine with metformin and/or 
pioglitazone. One important aspect to highlight is the 
inclusion of patients ‘failing’ on insulin glargine plus 
oral medication, defined as FPG  <121  mg/dL with high 
HbA1c, meaning that prandial intensification was likely 
needed. In these patients, further titration of insulin 
glargine may increase the risk of hypoglycemia. While 
we did not make any statistical comparisons in this post 
hoc analysis due to the limited sample size, numeri-
cal improvements in HbA1c after 24 weeks, likely to be 
clinically relevant, were observed with both LM25 and 
IGL. Our approach is consistent with the ALAD guide-
lines for intensifying insulin therapy in patients with 
HbA1c  >7.0  % and our results suggest that both LM25 
and IGL can be effective for lowering HbA1c in Latin 
American patients with T2DM who have blood glucose 
levels not adequately controlled on oral agents and basal 
insulin.
Fig. 2 HbA1c levels in participants receiving LM25 or IGL. Observed 
HbA1c levels at baseline, week 12, and week 24 in participants receiv-
ing LM25 or IGL. Values in boxes denote mean HbA1c. HbA1c glycated 
hemoglobin, IGL once-daily basal insulin glargine plus once-daily 
prandial insulin lispro, LM25 75 % insulin lispro protamine suspension 
and 25 % insulin lispro solution
Fig. 3 7-point SMBG levels at baseline and week 24. Mean unadjusted 7-point SMBG levels at baseline and week 24 in Latin American participants 
with type 2 diabetes mellitus who were treated with LM25 or IGL for 24 weeks. Error bars indicate standard deviation. IGL once-daily basal insulin 
glargine plus once-daily prandial insulin lispro, LM25 75 % insulin lispro protamine suspension and 25 % insulin lispro solution, SMBG self-monitor-
ing of blood glucose
Page 6 of 8Rojas et al. Diabetol Metab Syndr  (2016) 8:69 
The reduction in HbA1c levels after 24 weeks of treat-
ment experienced by both groups in the Latin American 
subpopulation is consistent with, and numerically higher 
than, the trial-level results in participants of various 
countries and ethnicities, which showed LM25 to be non-
inferior, and subsequently superior, to IGL with respect 
to glycemic control as measured by the change in HbA1c 
over the 24-week treatment period [12]. In keeping with 
the primary efficacy finding, improvements in secondary 
efficacy outcomes, including the proportion of partici-
pants who achieved HbA1c targets and SMBG, were also 
observed in the 2 study groups in the Latin American 
subpopulation. The secondary efficacy outcome results 
are also consistent with the trial-level findings [12].
Our observation that FPG increased and HbA1c 
decreased from baseline in both treatment groups 
appears somewhat paradoxical. This phenomenon was 
Table 2 Total daily, basal, and  prandial insulin doses 
at baseline and week 24
IGL once-daily basal insulin glargine plus once-daily prandial insulin lispro, 
IU international units, LM25 75 % insulin lispro protamine suspension and 25 % 
insulin lispro solution, SD standard deviation
a Baseline in this table is defined as day 1 post-randomization
Insulin dose LM25 (N = 80) IGL 
(N = 82)
Total daily insulin dose (IU), mean (SD)
 Baselinea 40.0 (19.2) 43.9 (18.8)
 Week 24 61.0 (27.6) 60.6 (24.3)
Daily basal insulin dose (IU), mean (SD)
 Baselinea 30.0 (14.4) 39.8 (18.8)
 Week 24 45.8 (20.7) 46.3 (20.2)
Daily prandial insulin dose (IU), mean (SD)
 Baselinea 10.0 (4.8) 4.2 (0.8)
 Week 24 15.3 (6.9) 14.4 (6.6)
Table 3 Reported hypoglycemia in study participants
IGL once-daily basal insulin glargine plus once-daily prandial insulin lispro, LM25 75 % insulin lispro protamine suspension and 25 % insulin lispro solution, 
SD standard deviation













Overall (≤70 mg/dL) 57 (71.3) 18.9 (27.3) 56 (68.3) 21.6 (31.1)
Documented symptomatic 
(≤70 mg/dL)
45 (56.3) 9.6 (15.5) 40 (48.8) 11.0 (19.4)
Asymptomatic (≤70 mg/dL) 36 (45.0) 8.5 (17.9) 43 (52.4) 10.2 (20.9)
Nocturnal 24 (30.0) 2.4 (5.8) 22 (26.8) 2.8 (6.5)
Severe 1 (1.3) 0.1 (0.7) 0 (0) 0 (0)
Table 4 Changes in ITSQ and PAM-D21 questionnaire scores
IGL once-daily basal insulin glargine plus once-daily prandial insulin lispro, ITSQ insulin treatment satisfaction questionnaire, LM25 75 % insulin lispro protamine 
suspension and 25 % insulin lispro solution, PAM-D21 perceptions about medications-diabetes 21, SD standard deviation
Variable, change from baseline LM25 (N = 80) IGL (N = 82)





 Inconvenience of regimen 92.7 (10.7) −1.5 (11.0) 92.2 (12.1) 0.5 (11.2)
 Lifestyle flexibility 82.9 (21.2) −0.1 (24.1) 84.7 (17.6) −4.8 (24.9)
 Glycemic control 80.9 (19.9) 6.9 (20.0) 78.3 (21.7) 10.3 (22.1)
 Hypoglycemic control 85.5 (14.7) −2.7 (17.7) 85.7 (17.8) 0.1 (17.0)
 Insulin delivery device satisfaction 86.9 (15.7) 4.2 (16.1) 88.6 (14.3) 1.1 (10.6)
 Total score 86.5 (11.4) 1.1 (11.6) 86.8 (12.4) 1.2 (10.6)
PAM-D21, mean (SD)
 Convenience/flexibility 90.0 (16.0) −0.7 (21.2) 91.7 (13.8) −1.2 (16.8)
 Perceived effectiveness 74.6 (20.7) 5.9 (23.7) 72.0 (20.5) 12.0 (25.4)
 Emotional effects 84.2 (20.2) 1.0 (21.7) 86.8 (17.5) −0.2 (22.4)
 Physical effects 87.0 (13.4) 1.0 (12.8) 90.5 (12.9) 1.1 (10.4)
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numerically greater in the LM25 group. Findings from a 
previous study suggested that the relative contribution 
of postprandial glucose to HbA1c increases as glyce-
mic control improves, whereas the contribution of FPG 
increases as diabetes worsens [16]. Based on FPG, the 
patients in this study were already optimized on glargine, 
therefore, the benefit was most likely due to the post-
prandial component with both intensification strategies.
We observed a trend for numerically lower blood glu-
cose concentrations before lunch in the LM25 group 
compared with the IGL group. This difference in before-
lunch blood glucose was also observed at a numerically 
lower level in the trial-level results [12]. Interestingly, in 
another study (DURABLE), Hispanic participants had 
significantly lower postprandial glucose after breakfast 
compared with the Caucasian participants [17]. Patients 
in Latin America vary with respect to the timing of their 
main daily meal. LM25 was administered before morning 
and evening meals in both our study and the DURABLE 
trial, regardless of when the main meal was consumed. 
Administering LM25 and then consuming a small meal, 
or a meal with high levels of dietary fiber or a low glyce-
mic index at breakfast time, as is common in Argentina, 
could account for the lower blood glucose concentrations 
observed in Hispanic and Latin American participants 
[18]. Conversely, consuming only breakfast and dinner, 
as is common in Mexico, may also result in low blood 
glucose during the day; however, administering LM25 
at breakfast and dinner in this situation could be appro-
priate. Importantly, a recently published subanalysis of 
the trial-level results demonstrated that glycemic con-
trol improved in patients receiving either LM25 or IGL, 
regardless of the timing of the main daily meal [19].
Despite the lower blood glucose concentrations before 
lunch with LM25 and the general concern that premixed 
insulin may increase the risk of hypoglycemia [20], we 
found that, while the rates of hypoglycemia in the Latin 
American subpopulation were numerically higher than 
those observed in the trial-level population [12], both the 
incidence and rate of hypoglycemia during the study were 
similar between the 2 study groups. It is important to note 
that these similar rates of hypoglycemia were observed in 
the context of a 0.5  % difference in HbA1c. Only 1 par-
ticipant experienced severe hypoglycemia and this did not 
result in a discontinuation. The numerically higher overall 
rate of hypoglycemia may be explained by specific dietary 
patterns, exercise habits, or cultural practices in the Latin 
American population. It is also notable that the mean 
insulin dose was numerically higher in this Latin Ameri-
can population compared with the trial population [12]. 
This higher dose may have contributed to the numerically 
higher rates of hypoglycemia observed in this analysis.
We also found that participants in the LM25 group 
gained more weight over the 24-week treatment period 
than participants in the IGL group. This trend was also 
observed in the trial-level results (LM25  =  1.13  kg, 
IGL  =  0.50  kg) [12]; however, the difference between 
treatments was more pronounced in the Latin Ameri-
can subgroup. One reason for this may be that patients 
can overeat to avoid hypoglycemia, particularly in cases 
where a frugal breakfast is eaten, which is often the case 
in Argentina and Brazil. Our finding of increased weight 
gain with LM25 should be considered within the broader 
context of improved glycemic control and the absence 
of specific recommendation for the management of diet 
and exercise in the management of weight in patients 
with T2DM [11]. The numerically higher insulin dose 
observed in this Latin American subpopulation com-
pared with the trial-level population [12] may also have 
contributed to the weight gain observed in this analysis.
This subanalysis of a multinational study has a number 
of strengths, including the prospective, multisite, mul-
ticountry, randomized design and the Latin American 
study population, which permits the exploration of the 
efficacy of insulin regimens in patients with varied meal 
patterns. As with most clinical trials of insulin, our study 
also has a number of limitations including: the post hoc 
nature of the analysis and open-label design of the study; 
the fact that the 2 insulin regimens used different injec-
tion devices and had different dosing requirements; the 
fixed distribution of doses at breakfast and dinner, which 
may have been better given at different times in some 
regions; and the relatively small sample size in each of the 
3 Latin American countries. The study was not powered 
to compare the ethnic subgroups within the study pop-
ulation and, therefore, no statistical comparisons were 
made between groups. The differences in prescribing 
practices, dietary habits, and clinical guidelines among 
Latin American countries mean that the results of this 
post hoc analysis may not be generalizable to other Latin 
American countries.
Conclusions
Intensification of insulin therapy with either LM25 
or IGL improved HbA1c in Latin American patients 
with T2DM who had not achieved target HbA1c on 
once-daily basal insulin glargine with metformin and/
or pioglitazone. The overall safety profile was simi-
lar between groups. The results of this study add to 
the body of evidence that supports the current ALAD 
guidelines, which recommend both insulin regimens 
as an option for insulin intensification in patients who 
do not achieve target HbA1c on basal insulin with oral 
antidiabetic drugs.
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